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Background: Prostate cancer is the second most common cause of cancer worldwide after lung cancer. There is
increasing evidence that diet and lifestyle plays a crucial role in prostate cancer biology and tumourigenesis. Prostate
cancer itself represents a good model of cancer in which to look for chemopreventive agents due to the high disease
prevalence, slowly progressive nature, and long latency period. Dietary agents have gained considerable attention,
often receiving much publicity in the media.
Aim: To review the key evidence available for potential chemopreventive nutrients.
Methods: The methodology for this review involved a PubMed search from 1990 to 2013 using the key-words
“diet and prostate cancer”, “nutrition and prostate cancer”, “dietary factors and prostate cancer”, “prostate cancer
epidemiology”, “prostate cancer prevention”, “prostate cancer progression”.
Results: Red meat, dietary fat and milk intake should be minimised as they appear to increase the risk of prostate
cancer. Fruit and vegetables and polyphenols may be preventive in prostate cancer, but further studies are needed
to draw more solid conclusions and to clarify their role in patients with an established diagnosis of prostate cancer.
Selenium and vitamin supplements cannot be advocated for the prevention of prostate cancer and indeed higher
doses may be associated with a worse prognosis. There is no specific evidence regarding benefits of probiotics or
prebiotics in prostate cancer.
Conclusions: From the wealth of evidence available, many recommendations can be made although more
randomised control trials are required. These need to be carefully designed due to the many confounding factors
and heterogeneity of the population.
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Despite many advances in the treatment of prostate can-
cer, little is known about the aetiological factors associ-
ated with both its development and progression. It is
now the second most common cancer in men world-
wide. In 2008, 899,000 men were diagnosed with pros-
tate cancer worldwide, with two thirds of cases seen in
the developed world [1]. There is also evidence of in-
creased incidence in immigrant populations to the US
and Europe compared to their countries of origin [2].
African American’s have among the highest prostate
cancer rates in the world [3], but a study by Chu et al.* Correspondence: m.caplin@ucl.ac.uk
1Centre for Gastroenterology, Royal Free Hospital, Pond Street, London NW3
2QG, UK
Full list of author information is available at the end of the article
© 2014 Mandair et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.comparing incidence rates across Africa found that al-
though there is considerable variability according to re-
gion, prostate cancer rates were still significantly lower
than amongst African Americans [4]. There are both
hereditary and environmental factors that contribute to
prostate carcinogenesis but at present only age, race,
and family history are established risk factors [5]. There
is increasing evidence from epidemiologic surveys and
from laboratory, intervention, and case–control studies
that diet and lifestyle plays a crucial role in prostate can-
cer tumourigenesis. Many nutrients and supplements
show potential benefit in helping to slow progression
and reduce recurrence, as well as complementing con-
ventional treatment to improve quality of life. Despite
the vast amounts of information available, a common
consensus on which nutrients may be beneficial andl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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plicated by the publication of these articles in the media
without appropriate human data available, which can
then lead to confusion for both patient and clinician.
Here we review the key evidence for the role of different
dietary components and nutrients on prostate cancer
prevention and progression.
Methods
A PubMed search was performed for publications from
1990 through 2013, using the following key words, in-
cluding both medical subject heading (MeSH) terms and
free language words/phrases: “diet and prostate cancer”,
“nutrition and prostate cancer”, “dietary factors and
prostate cancer”, “prostate cancer and epidemiology”,
“prostate cancer and prevention”, “prostate cancer and
progression”. No language restriction was applied. Refer-
ence lists from studies selected by the electronic search
were manually searched to identify further relevant re-
ports. Reference lists from all available review articles,
primary studies and proceedings of major meetings were
also considered. The most relevant nutrients and dietary
factors were determined by the level of evidence available,
with a minimum level of at least >1 than level IIB evidence
as per Scottish intercollegiate guidelines network (SIGN)
methodology. The quality and strength level of the results
were considered, and we focused the review on meta-
analyses and systemic reviews, large epidemiological
studies, well designed control or case cohort studies and
randomised control trials. If neither of these existed for a
nutrient or dietary factor that was frequently purported to
have a role in tumourigenesis in other cancers or had re-
ceived media coverage, then the most relevant in vivo and
in vitro studies were included. Information on clinical trials
was sourced from URL: http://clinicaltrials.gov/.
Results
There were a very large number of results returned for
each of our search parameters. After filtering for year
range, human studies, and article type, the number of
articles were as 1058 for “diet and prostate cancer”, 406
for “nutrition and prostate cancer”, 447 for “dietary fac-
tors and prostate cancer”, 9965 for “prostate cancer and
epidemiology”, 2800 for “prostate cancer and preven-
tion”, and 5743 for “prostate cancer and progression”.
After we manually screened for full text articles and
for documents that were specific for the scope of this
systematic review, we identified a total of 85 pertinent
articles with the strongest level of evidence. In more de-
tail, we considered 14 articles for “meat”, 11 articles for
“fatty acids”, 7 articles for “milk intake”, 14 articles for
“fruit and vegetables”, 11 articles for “polyphenols”, 21
articles for “selenium and vitamin supplements” and 6
articles for “probiotics and prebiotics”.Meat
Red Meat, Well cooked and Processed Meat has been
suggested to increase the risk of developing many can-
cers, in particular colorectal and prostate cancer. The
mechanisms are thought to involve the generation of
Heterocyclic Amines (HCAs) and haem compounds
catalysing oxidative damage. HCA’s are produced when
creatinine reacts with amino acids and sugars at high
temperatures [6]. The longer the meat is cooked and at
higher temperatures results in a greater number of HCAs
being generated [7]. HCAs have been documented as be-
ing some of the most potent mutagens detected using the
Ames/salmonella test [8]. Previous in vivo studies have
demonstrated the increased incidence of breast, colorectal
and prostate tumours in animals fed high HCA diets, par-
ticularly 2-amino-1-methyl-6-phenylimidazo (4,5-b) pyri-
dine (PhIP) [9]. The greater fat content in red meat
compared to white may be an additional factor in pro-
moting carcinogenesis [10].
Many large cohort studies of meat intake have taken
place worldwide in the last 20 years with conflicting re-
sults. A meta-analysis by Alexander et al. looked at pro-
spective studies examining the association between red
or processed meat and prostate cancer. Fifteen studies
on red meat and 11 on processed meat were included
but no association between them and prostate cancer
was found [11]. A previous meta-analysis published in
2009 on well-cooked meat and all cancer risk, looked at
four studies that examined HCA intake and prostate
cancer and concluded there was a positive association
with prostate cancer [6].
In a large prospective cohort study conducted at 10
U.S. centers, meat intake, cooking methods and whether
cooked till well done was assessed for approximately
29,000 in a National Cancer Institute sponsored cancer
screening trial. During the follow-up period, 868 incident
prostate cancer cases were identified. A high intake dose–
response relation was found for intake of very well-done
meat and exposure to PhIP [12]. In another cohort study
conducted in the United States, a positive association was
also found between high intake of well or very well-done
meat and more aggressive prostate cancer [13].
The European Prospective Investigation into Cancer
and Nutrition (EPIC)-Heidelberg cohort included a total
of 11,928 men aged 40–65 years and 13,612 women aged
35–65 years who were recruited between 1994 and 1998
from Heidelberg and its surrounding communities. In-
formation on diet, lifestyle, and health was obtained at
baseline by means of questionnaires and face-to-face
interviews. 337 incident cases of prostate cancer (123
advanced cases) were identified among 9,578 men with
valid dietary information. Surprisingly there was no associ-
ation between HCA intake and advanced prostate cancer
or between high consumption of strongly browned meat
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to the previous epidemiological studies, however its
findings could be explained in part by genetic poly-
morphisms that affect metabolism of HCAs, and thus
their potential carcinogenic effect [15]. This was sug-
gested in a follow-on case–control study looking again
at the EPIC Heidelberg group. All incident cases up to
February 2007 were included, which numbered 204 and
compared to 360 matched controls. Blood samples were
collected for genotyping and they found that the associ-
ation between HCA intake and prostate cancer risk could
be modified by polymorphisms of the genes that encode
for HCA metabolizing enzymes such as GSTT1, GSTM1,
and MnSOD. Patients with two or more deletions of
GSTT1 and GSTM1 genes were found to have a higher
risk of prostate cancer. Whilst a single nucleotide poly-
morphism (SNP) in MnSOD could also result in a higher
risk of prostate cancer due to loss of some if its antioxi-
dant properties [16].
More recently two studies have been published which
support the positive association with well done meat and
prostate cancer. Di Maso et al. analysed data from a net-
work of case–control studies conducted in Italy and
Switzerland between 1991 and 2009 (i.e. 1294 prostate
cancers) and found that risk of prostate cancer was in-
creased for meat cooked by roasting/grilling [17].
A systematic review by Gathirua-Mwangiet et al. sug-
gested that the habitual consumption of a diet high in
meat that was well-cooked was associated with an in-
creased risk for advanced prostate cancer, whilst an in-
consistent association was observed for intake of total
meat [18].
Arab et al. analysed the effect of adherence to the
World Cancer Research Fund (WCRF) lifestyle rec-
ommendations on the risk of highly aggressive pros-
tate cancer in research subjects enrolled in the North
Carolina-Louisiana Prostate Cancer Project. This in-
cluded 2212 newly diagnosed African Americans or
Caucasian Americans aged 40–70 years. They reported
that consumption of <500 g red meat per week was a sta-
tistically significant protective factor in the overall cohort
against development of prostate cancer [19].
In light of the available evidence, it is appropriate to
suggest limiting intake of well-cooked and processed
meat. Red meat should also be limited although the
studies are often contradictory, lower intake appears to
be associated with reduced risk of prostate cancer. Fu-
ture studies may benefit from looking for genetic poly-
morphisms of enzymes that metabolise HCA’s.
Conclusion: well-done meat appears to be associated
with an increased risk of prostate cancer and should
intake should be restricted. Consumption of <500 g red
meat per week may be suggested as a potential chemo-
preventive strategy.Dietary fat
Dietary Fat has a role in carcinogenesis but the exact
mechanisms are poorly understood.
This observation has been confirmed by Huang et al.
who investigated the effects of different diets on prostate
cancer cell growth using the in vivo and ex vivo model
and found that a diet with a high fat intake is associated
with increased prostate cancer cell growth. Moreover, they
suggested that the serum monocyte chemo-attractant
protein-1 (MCP-1) and the CC chemokine receptor 2
(CCRC2) signalling pathway may be involved in prostate
cancer progression secondary to high fat diet intake [20].
Different fat subtypes may play a different role in the
development of prostate cancer. According to a recent
systematic review, total fat intake and in particular, satu-
rated fat intake are significantly associated with an in-
creased risk for advanced prostate cancer, whilst dietary
intake of monounsaturated fat, polyunsaturated fat, and
linoleic acid is not associated with advanced prostate
cancer risk [18].
Persel et al. recently suggested that the effect of diet-
ary fat on risk of prostate cancer might differ according
to prostate cancer severity. They analysed associations
between dietary fats and fatty acids and risk of pros-
tate cancer in the NIH-American Association of Retired
Persons (AARP) Diet and Health Study, which in-
cluded 23,281 prostate cancer incident cases (18,934 non-
advanced and 2,930 advanced including 725 fatal cases)
among 288,268 men with a median follow-up of nine
years. This study showed that saturated fat and α-linoleic
acid (ALA) intakes were related to the risk of advanced or
fatal prostate cancer but not to non-advanced prostate
cancer [21].
The possible association between ALA and aggressive
prostate cancer has been suggested by a recent study by
Azrad et al. who found a positive association between
high prostatic ALA levels and more aggressive prostate
cancer. They found this was independent of the amount
of ALA consumed and suggested this could be due
to genetic polymorphism in enzymes related to ALA
metabolism [22].
Brasky et al. in a large, prospective study found that a
high concentration of serum phospholipid long-chain
lω-3 polyunsaturated fatty acids (LCω-3PUFA) was asso-
ciated with statistically significant increases in prostate
cancer risk, which suggests a role for these fatty acids in
prostate tumourigenesis [23]. These are contradictory to
the perception that LCω-3 PUFA’s have many beneficial
physiological effects and are considered to be anti-
inflammatory [24]. Within the same study they found
inconsistent results for ALA and arachidonic acids. These
are primary ω-6 fatty acids usually associated with in-
creased inflammation [25]. These findings have been con-
firmed by a recent case–control study, which showed that
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cancer risk [26].
Phytanic acid is a saturated fatty acid found predomin-
antly in red meats and dairy products. A prospective co-
hort study looking at the phytanic acid content of foods
consumed in the ATBC (Alpha-Tocopherol and Beta
Carotene) study found there to be a positive association
between high intake and development of prostate cancer
[27]. Although small proof of concept studies have found
there may be an inhibitory role for a low fat diet on
prostate cancer cells, more recent epidemiological studies
have not found this to be the case. The European Pro-
spective Investigation into Cancer and Nutrition (EPIC)
study included 142500 men and with a median follow up
of 8.7 years, 2727 patients were found to have prostate
cancer. They found no association between intake of diet-
ary fat and prostate cancer incidence [28].
A recent prospective study analysed 4577 men with non-
metastatic prostate cancer in the Health Professionals
Follow-up Study (1986–2010) and reported that re-
placing carbohydrates and animal fat with vegetable fat
(heterogeneous mix of monounsaturated and polyunsatur-
ated fats) may reduce the risk of all-cause mortality [29].
Conclusion: High fat intake (mainly saturated fatty
acids and linoleic acid) appears to be associated with an
increased risk of prostate cancer. The extent of this asso-
ciation may be difficult to interpret due to the heterogen-
eity in fat subtypes and grade of prostate cancer severity.
Milk & dairy products
Excessive consumption of milk and dairy products has
been postulated to increase the risk of developing pros-
tate cancer. This is thought to be a due to a combination
of the fat intake, suppression of circulating 1,25 dihy-
droxyvitamin D3 which can inhibit cellular proliferation
and promote apoptosis and also the increase in insulin-
like growth factor-1 from milk containing oestrogen
[30]. Recently there was much media coverage of an
Icelandic study that looked at milk consumption in
8,894 men born between 1907 and 1935. The study dem-
onstrated that higher daily milk consumption in adoles-
cence (vs. less than daily), but not in midlife or currently
was associated with a 3.2-fold risk of advanced prostate
cancer (95% CI: 1.25, 8.28) [31]. These striking results
confirm what has been suggested in previous epidemio-
logical studies. A meta-analysis of studies published be-
tween 1984 and 2003 resulted in a combined odds ratio
for milk consumption and prostate cancer of 1.68 [32].
Cell line work has also found milk to stimulate the
growth of prostate cancer in culture most recently dem-
onstrated by Tate et al. Interestingly, they found that al-
mond milk had a suppressive effect on cancer cell growth
[33]. Although no randomised control trials have demon-
strated milk exclusion having an impact on incidence, itcan be safely inferred from these studies that too much
milk and dairy product consumption can increase the
risk of prostate cancer and should be avoided. In those
patients with established prostate cancer, as yet there is
no evidence to recommend that excluding milk and dairy
from their diet will have any effect on progression. In-
deed, a recent study by Petterson et al. found that in a
cohort of 3,918 prostate cancer patients, intake was not
associated with an increased rate of progression in either
early, late or lethal prostate cancer [34].
In their recent prospective cohort study, Song et al.
confirmed previous findings and also analysed the effects
of different types of milk. They showed that higher
intake of skimmed/low-fat milk was associated with a
greater risk of non-aggressive prostate cancer. Whole-fat
milk was consistently associated with higher incidence
of fatal prostate cancer and higher prostate cancer-
specific mortality among cases [35].
A recent study by Travis et al. investigated the hypoth-
esis that a genetic polymorphism in the lactase gene
might be associated with elevated dairy product intake
and increased prostate cancer risk in a case–control
study nested within the EPIC study. The study included
630 men with prostate cancer and 873 matched control
participants. They found that lactase genotype frequency
varied significantly between countries, with frequencies
of the T (lactase persistence) allele ranging from 7% in
Greece to 79% in Denmark. The lactase variant was as-
sociated with milk intake in men, whilst it was not sig-
nificantly associated with prostate cancer risk [36].
Conclusion: milk intake, particularly during adoles-
cence appears to be associated with increased risk of
prostate cancer and its intake should be minimised.
There are no definite data on the effect of milk intake on
tumour progression.
Fruit and vegetables
Tomatoes and tomato based products such as ketchup
and purees have attracted a lot of interest in prostate
cancer. Tomatoes contain lycopene that give them their
colour and are one of the main carotenoids consumed in
the western diet. It is a powerful antioxidant but may
have additional properties in DNA repair that may add
to its role as a chemopreventive agent. A meta-analysis
in 2004 looked at 21 epidemiological studies related to
lycopene and found a weakly protective effect against
prostate cancer [37]. Animal studies have shown con-
flicting results but in vitro work has identified pathways
where lycopene plays an anti-carcinogenic role. There
have been Phase I and Phase II studies that have pro-
vided interesting results. A randomised, double-blind,
placebo-controlled, one-year study of lycopene 4 mg
twice daily was conducted in 40 patients with evidence of
HGPIN (high-grade prostatic intraepithelial neoplasia) at
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tate cancer reduction after one year of treatment was
66%. Lycopene was considered an effective chemopre-
ventive agent in the treatment of HGPIN, with no tox-
icity and good tolerability [38]. The FDA carried out a
review of 13 observational studies in 2007 and con-
cluded that at present, there was only limited evidence
to support tomatoes and lycopene consumption to de-
crease the risk of prostate cancer and that larger stud-
ies are required [39].
A recent meta-analysis included eleven cohort studies
and six nested case–control studies and showed that to-
mato may play a modest role in the prevention of pros-
tate cancer [40].
Conclusion: Tomatoes and tomato-based products may
be preventive in early prostate cancer. Patients with
high-grade benign prostate hyperplasia may benefit from
increased intake. Further research is needed to determine
the type and optimal quantity of tomato products re-
quired for prevention against prostate cancer.
Cruciferous vegetables are a group of vegetables
named for their cross-shaped flowers, and include cab-
bage, broccoli, brussel sprouts, cauliflower and wasabi.
The active components thought to be responsible for
their anti-cancer properties are isothiocyanates [41].
They have demonstrated induction of cell cycle arrest,
inhibition of tumor invasion and angiogenesis, anti-
inflammatory activity and inhibition of extracellular
signal-regulated kinases in both in vitro and in vivo
studies [42-44]. Previous epidemiological studies have
found some beneficial effects on the prevention of pros-
tate cancer but incorporation of these studies into meta-
analyses had not demonstrated a clear benefit. Recently
Bosetti et al. looked at 7 cohort and 6 population-based
case–control studies, and found that a significantly de-
creased prostate cancer risk was observed overall in the
cruciferous vegetables intake group (relative risks = 0.90;
95% confidence interval 0.85–0.96), but not in the sub-
group of cohort studies [45].
Conclusion: cruciferous vegetables may be beneficial
but more randomised controlled studies are needed, thus
they currently cannot be advocated for prostate cancer
prevention.
Pomegranate has been regarded as nature “power-
house fruit” from the tree Punica Granatum. Its juice
contains high concentrations of both tannin and flavon-
oid anti-oxidants, significantly higher than those seen in
green tea and red wine. Both in vitro and in vivo studies
have demonstrated an anti-tumour and anti-proliferative
effect. A large multi-centre study performed in 2004
looked at the effect of three preparations of pomegranate
supplements on three prostate cancer cell lines and on a
xenograft model. This found significant anti-tumour
properties of pomegranate mediated by the induction ofapoptosis and changes in cell cycle [46]. A role for pom-
egranate polyphenols in the inhibition of gene expres-
sion in androgen receptors in advanced prostate cancer
cell models has also been demonstrated [47]. A phase II
study recruited 46 patients receiving treatment for pros-
tate cancer whom had rising PSA levels. They were
given 8 ounces of pomegranate juice daily and serial
PSA levels were taken. They found a significant pro-
longation of the PSA doubling time from a mean of
15 months to 54 months, along with a prolongation of
disease stabilisation [48].
Stenner-Liwen et al. conducted a phase IIb, double-
blinded, randomised placebo controlled trial in 102
patients with histologically confirmed prostate cancer.
Only patients with a PSA value ≥5 ng/ml were included.
Participants were given 500 ml of pomegranate juice or
500 ml of placebo beverage every day for a 4 week period,
followed by 250 ml of the pomegranate juice daily for an-
other 4 weeks. The study showed that consumption of
pomegranate juice as an adjunct intervention in men with
advanced prostate cancer did not result in significant PSA
declines, compared to placebo [49].
A recent randomised study looked at 70 men awaiting
radical prostatectomy who were given either taking ei-
ther pomegranate extract (POMx) or placebo tablets
daily, for up to four weeks before surgery. There were
no significant differences in the clinical or pathological
features of prostate cancer between each group at the
end of the study [50]. The authors did suggest that
greater accumulation of pomegranate metabolites within
prostate tissue might confer a protective benefit against
oxidative DNA damage.
Conclusion: pomegranate supplementation may have a
role in both prevention and delaying progression of pros-
tate cancer, but available data are conflicting and the
mechanisms involved are poorly understood.
Polyphenols
Isoflavones are a subclass of the flavonoid group, which
are polyphenolic substances with strong anti-oxidant
properties. Isoflavones occur in plants such as soybeans
and other legumes and nuts. The main soy-derived iso-
flavones are genistein, daidzein, and glycitein. They have
weak oestrogen-like properties so are also known as
phytoestrogens [51]. Soy intake is high amongst Asian
men who have a very low incidence of prostate cancer.
This has led to much interest into soy isoflavones as po-
tential chemopreventive agents or even as adjuvants to
drug treatment in patients with prostate cancer. In vitro
studies have found inhibitory effects on signaling path-
ways, oncogene expression and steroid metabolism [52].
This work has been well supported by in vivo work,
where a genistein-containing preparation reduced the
tumour growth of androgen-sensitive prostatic cancer
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[53]. A review by Messina et al. found that in 4 out of 8
studies, daily soy isoflavone intake was associated with a
decrease in PSA in patients with prostate cancer [52].
A recent systematic review included eight randomised
controlled trials and a meta-analyses of the two studies
that only included men with identified risk of prostate
cancer found a significant reduction in prostate cancer
diagnosis following administration of soy/soy isoflavones.
The other six studies included patients already diag-
nosed with prostate cancer and no significant benefit
was identified [54].
A randomised placebo-controlled trial was conducted
to examine the effect of soy isoflavone capsules (80 mg/d
of total isoflavones, 51 mg/d aglucon units) on serum
and tissue biomarkers in patients with localised prostate
cancer. Eighty-six men were randomised to treatment
with isoflavones or placebo for up to six weeks prior
to prostatectomy. Hamilton-Reeves et al. showed that
genes involved in cell cycle control and in apoptosis were
down-regulated in the treatment tumour tissues versus
the placebo control, whilst serum hormone levels, total
cholesterol, or PSA were not affected by short-term in-
take of soy-isoflavones [55].
As the age-adjusted incidence rate of prostate cancer
has been reported to be lower among Asians than Western
populations, a recent Japanese systematic review analysed
the association between isoflavones and risk of prostate
cancer, focusing on equol, which is converted from daidzein
by human intestinal flora and is biologically more active
than any other isoflavone aglycone. A significant associ-
ation of isoflavones and of equol-producers with a de-
creased risk of prostate cancer was found. The authors
suggested increasing the proportion of equol-producers by
changing the intestinal flora as a possible strategy for redu-
cing the risk of prostate cancer [56].
Conclusion: Soy-containing products may be chemopre-
ventive in prostate cancer but further studies are war-
ranted to clarify their impact on PSA, total testosterone,
free testosterone and sex-hormone binding globulin levels
in men with, or at risk of, prostate cancer.
Green Tea contains high concentrations of polyphe-
nols the most abundant of which is
Epigallocatechin gallate (EGCG). There is much inter-
est in the use of green tea as both a chemopreventive
agent and in decreasing progression in cancer. Mecha-
nisms of the anti-tumourigenic action of green tea in-
clude apoptosis and cell cycle arrest via alterations in the
mitogen-activated protein kinase, phosphatidylinositol-3-
kinase (PI3K)/Akt and protein kinase C pathways, inhib-
ition of inflammatory pathways such as cyclooxygenase-2
(COX-2)] and modulation of the insulin-like growth factor
(IGF) and androgen receptor axes [57]. Both in vivo and
in vitro studies have provided convincing evidence of thepotential benefits of EGCG from green tea. A recent
in vivo study showed that a combination of green tea
and quercetin, a methylation inhibitor, could improve
chemoprevention of prostate cancer with no observed side
effects [58].
It has been suggested that the lower incidence of pros-
tate cancer in Asian men may be due to the consump-
tion of green tea. A case–control study of 130 patients
with histologically confirmed adenocarcinoma of the
prostate and 274 controls without prostate cancer or any
other malignant disease found the adjusted odds ratio
(OR), relative to non-tea drinkers, was 0.28 for tea drink-
ing, 0.12 for those drinking tea over 40 years, 0.09 for
those consuming more than 1.5 kg of tea leaves yearly,
and 0.27 for those drinking more than 3 cups (1 litre)
daily. The study concluded that the risk of prostate can-
cer declined with increasing frequency, duration and
quantity of green tea consumption and that the dose–
response relationships were also significant when sug-
gesting that green tea was protective against prostate
cancer [59]. There are other much larger epidemiological
studies but these have taken place among Asian men
and there may be other confounding factors associated
with the lower risk of prostate cancer [60]. There have
been few randomised controlled trials examining the
response of green tea in patients with prostate cancer,
whilst those published have yet to demonstrate a clear
positive benefit [61].
Conclusion: Supplementation of the diet with Green
tea appears to have an effective chemopreventive agent
in prostate cancer, but there is no evidence to suggest any
beneficial effects in patients already with prostate cancer.
There may be benefit in those patients who have HGPIN.
Selenium and vitamin supplements
Selenium is an essential trace element with most intake
coming from crop and animal products, but high levels
are also found in brazil nuts, tuna, swordfish and mol-
luscs. There has been considerable interest in its antioxi-
dant properties and potential as a chemopreventive
agent since a large randomised control trial in the 1990’s
found it to be protective against the development of
many cancers [62]. This led to many epidemiological
studies, 21 of which were included in a meta-analysis by
Brinkman et al. whom demonstrated an increase in
prostate cancer in men with lower selenium levels [63].
Many in vitro studies have found Selenium to induce
apoptosis, inhibit cellular proliferation and inhibit angio-
genesis [64]. Unfortunately, the promising theory behind
selenium has not been demonstrated in randomised con-
trolled studies. The Selenium and Vitamin E Cancer
Prevention Trial (SELECT) found no reduction in risk of
prostate cancer with either selenium or vitamin E supple-
ments. This large study randomised 35,533 men from
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Rico to either selenium vs placebo, vitamin E vs placebo
or both vs placebo. Worryingly, an elevated risk with
vitamin E was found [65]. A possible explanation for
these null findings include the agent formulation and
dose, the baseline characteristics of the cohort and the
study design, which suggests that it is likely that only spe-
cific subpopulations may benefit from selenium supple-
mentation [66]. Furthermore, a recent phase III studies
of selenium vs placebo in patients with HGPIN found no
benefit in the prevention of progression to prostate can-
cer and suggested higher intake might increase the risk
of cancer [67]. There are of course confounding factors
that may influence the outcome of such studies such as
selenium status and genetic polymorphism of enzymes
involved in selenium metabolism [68]. A comprehensive
review by Venkastweran et al. of chemoprevention in
prostate cancer confirmed our conclusion that despite
encouraging in vivo and in vitro data, epidemiological
studies and the larger case–control studies had demon-
strated a need for caution in advocating selenium supple-
mentation until there is improved understanding of its
metabolism [69].
Conclusion: large randomised trials showed no role for
selenium supplementation in chemoprevention of pros-
tate cancer and emerging evidence suggests that high
levels may be pro-carcinogenic.
Vitamin E is a general term used to refer to a group
of naturally occurring compounds called tocopherols
and tocotrienols, as well as vitamin E derivatives such
asacetate, succinate, and nicotinate of both natural and
synthetic alpha tocopherol [70]. It’s strong antioxidant
and inhibitory properties were postulated to have a che-
mopreventive role in the development of many cancers.
The Alpha-Tocopherol and Beta-Carotene (ATBC) can-
cer study in 1994 demonstrated a one-third reduction in
prostate cancer incidence and a 41% reduction in pros-
tate cancer mortality among Finnish male smokers re-
ceiving Vitamin E. No significant difference was seen in
non-smokers given Vitamin E and no beneficial effects
were seen with Vitamin A [71]. In vitro studies have
followed, reporting encouraging results such as a 40%
drop in the number of cancer cells with 72 hr treatment
with vitamin E succinate [72]. In a study by Venkastweran
et al., an animal model of prostate cancer using lady trans-
genic mice found a significant reduction in incidence of
prostate cancer where mice were given vitamin E sup-
plementation [73]. A further study by the same group
found that mice given supplementation at an early stage
with Vitamin E, Selenium and Lycopene had only a 10%
incidence of prostate cancer compared to 75% in the
control group. A combination of Vitamin E and Selenium
was less effective but still resulted in decreased inci-
dence and improved overall survival in the mice [74].Unfortunately, this encouraging data has not been seen
in human studies and the SELECT study found that a
higher incidence of prostate cancer was seen in patients
given vitamin E supplementation [65].
Recently, Bauer et al. examined circulating vitamin E
and vitamin E-related genes in relation to the risk of
high-grade prostate cancer and prostate cancer recur-
rence among men diagnosed with organ-confined dis-
ease (35,533 men from the US, Canada, and Puerto Rico
were enrolled in a 3-year period). They found that germ
line genetic variation in genes of enzymes associated
with detoxification of free radicals may be associated
with the risk of high-grade disease at diagnosis and dis-
ease recurrence, which might suggest consideration of
such genotypes in the interpretation of vitamin E sup-
plementation trials such as SELECT. Additionally, circu-
lating γ-tocopherol levels may also be associated with an
increased risk of high-grade disease at diagnosis [75].
Conclusion: Vitamin E supplementation should not
be recommended as chemoprevention in prostate can-
cer at present, until better understanding of its biology
is available.
Vitamin A consists of Retinol and the carotenes; alpha-
carotene, beta-carotene, gamma-carotene, and the xan-
thophyll beta-cryptoxanthin. Induction of apoptosis by
retinoids has been observed in various prostate cancer
cells in vitro and in vivo [76]. However, large rando-
mised control trials have not found any protective bene-
fits and some studies have suggested an increase in
the incidence of various cancers with the use of mul-
tivitamins. The most significant was the Carotene and
Retinol Efficacy Trial (CARET), a multicentre rando-
mised, double-blind placebo-controlled chemoprevention
trial testing whether daily supplementation with 30 mg
β-carotene + 25,000 IU retinyl palmitate would reduce
lung cancer risk among 18,314 heavy smokers, former
heavy smokers and asbestos-exposed workers. Another
arm of the study was to look at prostate cancer. Men in
the interventional arm who also used additional dietary
supplements had an increased RR towards developing an
aggressive prostate cancer (RR 1.52, 95% CI 1.03–2.24;
P < 0.05) [77]. Although this study included only smokers
or former smokers, similar studies have suggested that
vitamin A and multivitamin supplements may increase the
risk of prostate cancer.
Conclusion: Vitamin A supplements are not recom-
mended as part of chemopreventive diet to prevent pros-
tate cancer.
Vitamin D There has been conflicting evidence about
the effect of Vitamin D on prostate Cancer. In vitro
studies suggest it may have a useful role in all types of
cancer in view of its antiproliferative properties and
potential to induce apoptosis. Dietary consumption of
Vitamin D can have a significant effect on circulating
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and both metabolites may have a chemopreventive po-
tential [78]. Many pre-clinical studies have found that
murine models of prostate cancer with vitamin D defi-
ciency show an increased rate of proliferation and of
growth in bone [79]. Epidemiological studies have sug-
gested there may be even be a U-shaped relationship
with vitamin D and prostate cancer, with very low levels
or very high levels associated with increased risk. A
study by Ahn et al. detected a significant linear increase
in the risk of aggressive prostate cancer for those with
25(OH) D concentrations higher than 42 nmol/L [80].
Much of the evidence is based upon epidemiological
studies, and although a U-shaped curve may be appar-
ent, more recent evidence suggests that Vitamin D has
neither a protective or causative role in prostate cancer
or in the development of metastases. A large meta-
analysis by Gilbert et al. in 2010 looked at 25 papers
from a database of over 24,000. It found there to be no
published literature that supported a strong role for high
or low vitamin D levels in either preventing prostate
cancer or its progression [81]. Holt et al. conducted a
population-based cohort study of 1476 prostate cancer
patients to assess disease recurrence/progression and
prostate cancer-specific mortality risks associated with
serum levels of 25(OH)D. During an average of 10.8 years
of follow-up, they found that serum levels of 25(OH) D
were not associated with risk of recurrence/progression
or mortality from prostate cancer [82]. A recent meta-
analysis, including thirty-four studies for a total of 10,267
cases and 11,489 controls, focused on the association be-
tween vitamin D receptor (VDR) polymorphisms, which
mediate the cellular effects of vitamin D and risk of pros-
tate cancer. No evidence to support an association betweenTable 1 Summary of current evidence on the relationship bet
prostate cancer
1. Well-done meat is associated with increased risk of prostate cancer; co
2. High fat intake (mainly saturated fatty acids and linoleic acid) appears
3. Milk intake appears to be associated with increased risk of prostate ca
4. Tomatoes and tomato-based products may be preventive in early pro
5. Cruciferous vegetables may be beneficial but they currently cannot be
randomized trials.
6. Pomegranate may have a role in both prevention and delaying progr
7. Soy-containing products may be chemopreventive in prostate cancer bu
and sex-hormone binding globulin levels in men with, or at risk of, prost
8. Green tea appears a chemopreventive agent in prostate cancer, but th
9. Selenium supplementation is not recommended in chemoprevention
10. Vitamin A is not recommended as part of chemopreventive diet to pr
11. Supplementation with vitamin D is not advocated unless the patient
worse prognosis.
12. There is no evidence regarding benefits of pre- or probiotics in prostaany of the VDR polymorphisms and risk of prostate cancer
was found [83]. Further studies have found there to be
no convincing association and random control trials are
lacking.
Conclusion: Vitamin D supplementation in prostate
cancer cannot be advocated unless the patient is defi-
cient, and even then must be replaced with care as higher
doses may be associated with a worse prognosis.
Prebiotics and probiotics
Prebiotics are defined as “non-digestible food ingredi-
ents that beneficially affect the host by selectively stimu-
lating the growth and/or the activity of one or a limited
number of bacteria in the colon” [84]. They are fermen-
ted by bacteria, benefiting the host by restoring appro-
priate microbial balance in the intestine. There are two
main groups of prebiotics; Oligosaccharides which are
fructooligosaccharides (FOS) and inulin, and maltooligo-
saccharides of which maldrexitin is most researched
[85]. Inulin-type fructans are present in foods such as
garlic, onion, artichoke and asparagus. There is little
data looking for chemopreventive use in prostate cancer,
whereas benefit has been proposed in other cancers, e.g.
colorectal cancer [86]. Possible mechanisms for a pro-
tective role in carcinogenesis include: (i) selectively pro-
moting the growth of bacteria such as bifidobacteria
which have a tumour suppressive effect (ii) the forma-
tion of reducing agents, such as glutathione which can
inactivate food-borne carcinogens (iii) decreasing levels
of certain bacterial enzymes purported to be involved in
activation of carcinogens (iv) the production of anti-
cancer metabolites such as short chain fatty acids (SCFA),
in particular butyrate (v) the up-regulation of apoptosis
(vi) causing a decrease in triglycerides, phospholipids andween dietary factors and supplements and risk of
nsumption of red meat should be limited to <500 g per week.
related to increased risk of prostate cancer.
ncer and its intake should be minimized.
state cancer.
advocated for prostate cancer prevention due to the paucity of
ession of prostate cancer, but available data are often conflicting.
t further studies are warranted to clarify their impact on PSA, testosterone,
ate cancer.
ere is inconclusive benefit in patients already with prostate cancer.
of prostate cancer and very high levels may indeed be pro-carcinogenic.
event prostate cancer.
is vitamin D deficient. High levels of vitamin D may be associated with a
te cancer.
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growth [87].
Probiotics are “live microorganisms, which, when ad-
ministered in adequate amounts, confer a health benefit
on the host” [88]. Probiotics have been shown to have
effects on irritable bowel, metabolic syndromes and
urogenital infections, and as potential chemopreven-
tive agents in colorectal cancer [86]. Possible mecha-
nisms in chemoprevention are similar to those of
prebiotics that promote a healthy microbial balance
in the intestine. They are also thought to have add-
itional roles in decreasing expression of cytokines and
upregulation of intestinal genes that are involved in nu-
trient absorption, mucosal barrier fortification, xeno-
biotic metabolism, and angiogenesis [89]. There have
been very few studies looking at a potential chemopre-
ventive role in prostate cancer, although there are many
human studies in colorectal cancer and some animal
studies in breast cancer.
Conclusion: Currently, although there are potential
general health benefits from supplementation with pre-
and probiotics, there is no direct evidence regarding ben-
efits in prostate cancer.
Conclusion
There is a wealth of scientific information available on
the potential role of diet in chemoprevention in prostate
cancer. Much of the data is encouraging and advocates
an important role for optimising intake of a wide variety
of nutrients. Herein, we analysed nutritional factors that
might play a role in the development of prostate cancer
(Table 1). There is evidence that consumption of red
meat, dietary fat and milk intake should be minimised,
as they appear to increase the risk of prostate cancer.
Fruit and vegetables and polyphenols (i.e. green tea and
soy-products) may be preventive in prostate cancer,
but further studies are needed to draw more solid con-
clusions and to clarify their role in patients with an
established diagnosis of prostate cancer. Selenium and
vitamin supplements cannot be advocated for the pre-
vention of prostate cancer and indeed higher doses may
be associated with a worse prognosis. There is no spe-
cific evidence regarding benefits of probiotics or prebi-
otics in prostate cancer, thus they cannot be advocated
in this setting.
There is a need for larger randomised control trials,
which will also help to identify optimal dose and dur-
ation of nutrients as well as potentially determine why
some sub-groups of patients may respond better than
others. However, heterogeneous populations with differ-
ing lifestyles, baseline nutritional characteristics, genetic
background and many other variables mean it is difficult
to design such studies in order to develop population-
based prevention strategies for prostate cancer.Competing interests
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